title: Evaluation of inhibitor antibody in hemophiliaA population.
abstract: BACKGROUND
  Inhibitor antibody to exogenous Factor VIII (FVIII) is a major complication of hemophilia treatment. This study was conducted to determine the prevalence of inhibitor antibody directed against FVIII.
  
  
  METHODS
  From May 2010 to May 2011, 52 patients with severe hemophilia A admitted in Amirkola Children's Hospital were evaluated. Those who had abnormal mixing study, antibody against FVIII were measured. Data were collected and analyzed.
  
  
  RESULTS
  The age range of the patients was 4-60 years. The inhibitor antibody was seen in 9 (17.3%) patients. The mean age of patients with inhibitor at the time of diagnosis was 10.22 years (ranged 4-31 years). Old patients had more hemarthrosis than young patients. The mean level of inhibitor antibody was 8.47 Bethesda unit (ranged 2.3-29). Six patients had inhibitor antibody level ≥5 Bethesda unit and three patients had inhibitor antibody level <5 Bethesda unit.
  
  
  CONCLUSIONS
  This study showed that the prevalence of inhibitor antibodies in young patients is more than the old patients.
authors.affiliation: Non- Communicable Pediatrics Diseases Research Center, Babol University of Medical Sciences, Babol, Iran.
authors.forename: Hassan
authors.initials: H
authors.lastname: Mahmoodi Nesheli
authors.forename: Amereh
authors.initials: A
authors.lastname: Hadizadeh
authors.forename: Ali
authors.initials: A
authors.lastname: Bijani
keywords: Hemarthrosis; Inhibitory antibody; concentrated FVIII; hemophilia A